Animal Cell Therapies specializes in the research and development of stem cell treatments aimed at addressing both acute and chronic diseases in companion animals. The company has focused on creating a standardized product derived from umbilical cord tissue, which is rich in mesenchymal stem cells (MSCs). These cells are known for their high proliferation rates and potent differentiation capabilities, making them a valuable resource for therapeutic applications. The company has invested a decade into refining its processes to ensure a consistent, pure, and effective product, which is supported by rigorous safety and efficacy data under the oversight of the FDA's Center for Veterinary Medicine.

The advantages of using umbilical cord tissue-derived stem cells are significant. The collection process is non-invasive, eliminating the need for costly surgical procedures typically associated with autologous sources like bone marrow or fat cells. This method not only reduces costs but also avoids ethical concerns related to the use of research animals, as the cords are sourced from client-owned dogs. The manufacturing process allows for rapid cell proliferation, resulting in a higher concentration of stem cells per dose. This innovative approach positions Animal Cell Therapies at the forefront of veterinary stem cell therapy, emphasizing both scientific rigor and clinical safety.

United States

Animal Cell Therapies engages in research and development of stem cell treatments for orthopedic and chronic diseases in dogs.

Animal Cell Therapies

Company Details